Capture rate and representativity of The National Prostate Cancer Register of Sweden

Figures & data

Table I. Demographics and comorbidity for men diagnosed with prostate cancer and registered in the National Prostate Cancer Register (NPCR) of Sweden, the Cancer Register only (CR Only), and the Cause of Death Register only (DC Only).

	NPCR N = 100 849	CR Only N = 2198	DC Only N = 1929
Region
Northern	10 376 (10%)	59 (3%)	196 (10%)
Uppsala Örebro	21 373 (21%)	135 (6%)	583 (30%)
Western	21 787 (22%)	207 (9%)	211 (11%)
Southern	17 647 (18%)	193 (9%)	374 (19%)
Southeastern	11 519 (11%)	149 (7%)	159 (8%)
Stockholm	18 147 (18%)	1455 (66%)	406 (21%)
Calendar period
1998–2000	20 494 (20%)	394 (18%)	444 (23%)
2001–2003	23 927 (24%)	491 (22%)	498 (26%)
2004–2006	28 564 (28%)	557 (25%)	459 (24%)
2007–2009	27 864 (28%)	756 (34%)	528 (27%)
*Age at diagnosis, years
< 65	31 089 (31%)	593 (27%)	50 (3%)
66–74	33 492 (33%)	667 (30%)	158 (8%)
75–79	17 244 (17%)	342 (16%)	231 (12%)
80–89	17 742 (18%)	519 (24%)	982 (51%)
90 +	1282 (1%)	77 (4%)	508 (26%)
Charlson Comorbidity Index
0	65 649 (65%)	1633 (74%)	630 (33%)
1	18 188 (18%)	287 (13%)	423 (22%)
2	9896 (10%)	164 (8%)	226 (12%)
3 +	7116 (7%)	114 (5%)	650 (34%)

*For men diagnosed with prostate cancer in the Cause of Death Register only, date of start of treatment was used as a proxy for date of diagnosis for 698 men who had been diagnosed after 2006, for the remaining 1 231 men, date at death was used.

Table II. Treatment for men diagnosed with prostate cancer in 2006–2009 and registered in the National Prostate Cancer Register, the Cancer Register only (CR Only), and the Cause of Death Register only (DC only).

	NPCR N = 36 967	CR Only N = 1020	DC Only N = 698
Treatment
*Androgen deprivation therapy	13 691 (37%)	312 (31%)	395 (57%)
Radical prostatectomy	10 111 (27%)	151 (15%)	0 (0%)
**Other treatments	13 165 (36%)	557 (55%)	303 (43%)

*Information on androgen deprivation therapy (ADT) was retrieved from the Prescribed Drug Register, which started on 1 July 2005. ADT included GnRH analogs and anti-androgens;

**other treatments include radiotherapy, conservative treatment (i.e. no active treatment including active surveillance and deferred hormonal treatment), and transurethral resection of the prostate. Treatment had not been registered for 1333 men.

Table III. Duration of perioperative hospital stay for radical prostatectomy for 19 683 men in the National Prostate Cancer Register, and 262 for men in the Cancer Register only (CR Only) registered 1998–2009.

	NPCR N = 19 683	CR Only N = 262
*Median stay in days (25th – 75th percentile)	5 (3–6)	4 (2–5)
< 3 days	2730 (14%)	71 (27%)
3 – 5 days	10069 (51%)	136 (52%)
6 – 7 days	4597 (23%)	33 (13%)
8 + days	2287 (12%)	21 (8%)

Figure 1. (a) Prostate cancer mortality and mortality from other causes for men diagnosed with prostate cancer and registered in the National Prostate Cancer Register. (b) Prostate cancer and all-cause mortality for men diagnosed with prostate cancer and registered in the Cancer Register only. (c) Prostate cancer mortality for 698 men diagnosed with prostate cancer and registered in the Cause of Death Register only. *Date of start of androgen deprivation therapy: GnRH analogs, anti-androgens, or orchiectomy.